Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North").

26 Nov 2013

Keeping active reduces women’s Crohn’s risk

Regular exercise protects women against the development of Crohn’s disease, reveals research published in the BMJ.

21 Nov 2013

Scientists receive $2.2M grant to improve treatments for immune disorders, inflammatory diseases

Scientists from the Walter and Eliza Hall Institute have been awarded more than $2.2 million from the Australian Research Council (ARC) to improve treatments for immune disorders and inflammatory diseases.

16 Nov 2013

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Antibe Therapeutics Inc. is proud to announce that Dr. John Wallace, the Corporation's Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today.

8 Nov 2013

Four-year study to develop targeted approach to psoriasis treatment

A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.

8 Nov 2013

Researchers identify new class of anti-inflammatory drugs may be used to treat IBD

Researchers in UCD Conway Institute and Systems Biology Ireland have identified a way that a new class of anti-inflammatory drugs may be used to treat inflammatory bowel disease (IBD).

7 Nov 2013

Leukemia drug reverses symptoms of colitis in lab tests

A drug currently on the market to treat leukemia reversed symptoms of colitis in lab tests, according to recently published findings by medical researchers with the University of Alberta.

24 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Good news: Knowing risk early, women can take action to prevent osteoporosis

On World Osteoporosis Day, October 20, the International Osteoporosis Foundation (IOF) is calling for women to take action now to protect their bone health. Broken bones due to osteoporosis often result in pain, immobility and loss of quality of life as well as early death.

17 Oct 2013

Study shows IBD patients may have increased risk of heart attack, stroke

Patients with inflammatory bowel disease are at an increased risk of stroke and heart attack according to a new study presented by Mayo Clinic researchers at the American College of Gastroenterology's Annual Scientific Meeting, Oct. 11-16, in San Diego.

15 Oct 2013

Change in gene expression occurs in patients with "pouchitis" after UC surgery

"Pouchitis" developing after surgery for ulcerative colitis (UC) is associated with changes in gene expression, which increase along with disease severity, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

11 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

Scientists have discovered that Crohn's disease, the inflammatory bowel disorder, can originate from specialised intestinal cell type called Paneth cells. As such, they propose that small intestinal Crohn's disease might be a specific disorder of this cell type, providing a possible new target for treatments.

3 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Researchers at Institut Hospital del Mar d'Investigacions M-diques (IMIM) in Barcelona, in collaboration with the Icahn School of Medicine at Mount Sinai in New York and other U.S. Institutions, have found that intestinal mucus not only acts as a physical barrier against commensal bacteria and dietary antigens, but also prevents the onset of inflammatory reactions against these agents.

27 Sep 2013

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

25 Sep 2013

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Immune Pharmaceuticals to transfer common stock listing from NASDAQ OMX Stockholm Exchange

Keeping active reduces women’s Crohn’s risk

Scientists receive $2.2M grant to improve treatments for immune disorders, inflammatory diseases

Antibe Founder and Chief Science Officer honored with Heymans Foundation Memorial Medal

Four-year study to develop targeted approach to psoriasis treatment

Researchers identify new class of anti-inflammatory drugs may be used to treat IBD

Leukemia drug reverses symptoms of colitis in lab tests

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Good news: Knowing risk early, women can take action to prevent osteoporosis

Study shows IBD patients may have increased risk of heart attack, stroke

Change in gene expression occurs in patients with "pouchitis" after UC surgery

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Intestinal mucus potentially improves life of people suffering from inflammatory bowel disease

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Abbvie, Galapagos Ink Up To $405M CF Collaboration

Abbvie, Galapagos Ink Up To $405M CF Collaboration

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in